The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use
Abstract
The sex hormone estrogen is important for many physiologic processes. Prolonged stimulation of breast ductal epithelium by estrogen, however, can contribute to the development and progression of breast cancer, and treatments designed to block estrogen’s effects are important options in the clinic. Tamoxifen and other similar drugs are effective in breast cancer prevention and treatment by inhibiting the proliferative effects of estrogen that are mediated through the estrogen receptor (ER). However, these drugs also have many estrogenic effects depending on the tissue and gene, and they are more appropriately called selective estrogen receptor modulators (SERMs). SERMs bind ER, alter receptor conformation, and facilitate binding of coregulatory proteins that activate or repress transcriptional activation of estrogen target genes. Theoretically, SERMs could be synthesized that would exhibit nearly complete agonist activity on the one hand or pure antiestrogenic activity on the other. Depending on their functional activities, SERMs could then be developed for a variety of clinical uses, including prevention and treatment of osteoporosis, treatment and prevention of estrogen-regulated malignancies, and even for hormone replacement therapy. Tamoxifen is effective in patients with ER-positive metastatic breast cancer and in the adjuvant setting. The promising role for tamoxifen in ductal carcinoma-in-situ or for breast cancer prevention is evolving, and its use can be considered in certain patient groups. Other SERMs are in development, with the goal of reducing toxicity and/or improving efficacy, and future agents have the potential of providing a new paradigm for maintaining the health of women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Cloning of a novel receptor expressed in rat prostate and ovary.
Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., & Gustafsson, J. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5925 · Cited by 4,788
Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β
Kuiper, G. G. J. M., Lemmen, J. G., Carlsson, B., Corton, J. C., Safe, S. H., van der Saag, P. T., van der Burg, B., & Gustafsson, J.-Å. (1998) · Endocrinology · doi:10.1210/endo.139.10.6216 · Cited by 4,203
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
ERβ: Identification and characterization of a novel human estrogen receptor
Mosselman, S., Polman, J., & Dijkema, R. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00782-x · Cited by 2,269
Kamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81118-6 · Cited by 2,150
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
Nuclear Receptor Coregulators: Cellular and Molecular Biology*
McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,911
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Differential Ligand Activation of Estrogen Receptors ERα and ERβ at AP1 Sites
Paech, K., Webb, P., Kuiper, G. G. J. M., Nilsson, S., Gustafsson, J.-Å., Kushner, P. J., & Scanlan, T. S. (1997) · Science · doi:10.1126/science.277.5331.1508 · Cited by 1,861
Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902233200802 · Cited by 1,464
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Self-citationFunctional domains of the human estrogen receptor
Kumar, V., Green, S., Stack, G., Berry, M., Jin, J.-R., & Chambon, P. (1987) · Cell · doi:10.1016/0092-8674(87)90581-2 · Cited by 1,316
Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., Cronin, W. M., & Contributors, O. N. (1994) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/86.7.527 · Cited by 1,268
The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129
(1991) · PubMed · Cited by 1,101
The human estrogen receptor has two independent nonacidic transcriptional activation functions
Tora, L., White, J., Brou, C., Tasset, D., Webster, N., Scheer, E., & Chambon, P. (1989) · Cell · doi:10.1016/0092-8674(89)90031-7 · Cited by 1,048
Fisher, B., Dignam, J., Wolmark, N., Wickerham, D. L., Fisher, E. R., Mamounas, E., Smith, R., Begovic, M., Dimitrov, N. V., Margolese, R. G., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05036-9 · Cited by 1,040
Nuclear receptor coactivators and corepressors
Horwitz, K. B. (1996) · Molecular Endocrinology · doi:10.1210/me.10.10.1167 · Cited by 942
ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS
Fornander, T., Cedermark, B., Mattsson, A., Skoog, L., Theve, T., Askergren, J., Rutqvist, L., Glas, U., Silfverswärd, C., Somell, A., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91141-0 · Cited by 920
Powles, T. (1998) · The Lancet · doi:10.1016/s0140-6736(98)05071-5 · Cited by 902
Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., Costantino, J., Redmond, C., Fisher, E. R., Bowman, D. M., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.21.1529 · Cited by 861
Veronesi, U. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04394-3 · Cited by 804
Barkhem, T., Carlsson, B., Nilsson, Y., Enmark, E., Gustafsson, J.-Å., & Nilsson, S. (1998) · Molecular Pharmacology · doi:10.1124/mol.54.1.105 · Cited by 779
Basic Guide to the Mechanisms of Antiestrogen Action
Macgregor, J. I., & Jordan, V. C. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01358-9 · Cited by 694
Webb, P. (1995) · Molecular Endocrinology · doi:10.1210/me.9.4.443 · Cited by 693
Estrogen Receptors α and β Form Heterodimers on DNA
Cowley, S. M., Hoare, S., Mosselman, S., & Parker, M. G. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.32.19858 · Cited by 689
Tzukerman, M. T. (1994) · Molecular Endocrinology · doi:10.1210/me.8.1.21 · Cited by 671
Smith, C. S., Nawaz, Z., & O’Malley, B. W. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.657 · Cited by 662
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2920 · Cited by 660
Self-citationPowles, T. J., Hickish, T., Kanis, J. A., Tidy, A., & Ashley, S. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.78 · Cited by 646
Black, L. J., Sato, M., Rowley, E. R., Magee, D. E., Bekele, A., Williams, D. C., Cullinan, G. J., Bendele, R., Kauffman, R. F., & Bensch, W. R. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116985 · Cited by 609
Pettersson, K., Grandien, K., Kuiper, G. G. J. M., & Gustafsson, J.-A. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.10.9989 · Cited by 597
Kumar, V., Green, S., Staub, A., & Chambon, P. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04489.x · Cited by 530
Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
McDonnell, D. P. (1995) · Molecular Endocrinology · doi:10.1210/me.9.6.659 · Cited by 526
The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling
Dauvois, S., White, R., & Parker, M. G. (1993) · Journal of Cell Science · doi:10.1242/jcs.106.4.1377 · Cited by 522
Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex
Fryer, C. J., & Archer, T. K. (1998) · Nature · doi:10.1038/30032 · Cited by 511
Ogawa, S., Inoue, S., Watanabe, T., Hiroi, H., Orimo, A., Hosoi, T., Ouchi, Y., & Muramatsu, M. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7893 · Cited by 510
BRCA1 Inhibition of Estrogen Receptor Signaling in Transfected Cells
Fan, S., Wang, J.-A., Yuan, R., Ma, Y., Meng, Q., Erdos, M. R., Pestell, R. G., Yuan, F., Auborn, K. J., Goldberg, I. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1354 · Cited by 491
Jackson, T. A., Richer, J. K., Bain, D. L., Takimoto, G. S., Tung, L. W., & Horwitz, K. B. (1997) · Molecular Endocrinology · doi:10.1210/me.11.6.693 · Cited by 478
Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover.
Dauvois, S., Danielian, P. S., White, R., & Parker, M. G. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.9.4037 · Cited by 465
Nawaz, Z., Lonard, D. M., Smith, C. L., Lev-Lehman, E., Tsai, S. Y., Tsai, M.-J., & O’Malley, B. W. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1182 · Cited by 452
Steroid hormone receptors in breast cancer management
Osborne, C. K. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006132427948 · Cited by 438
Self-citationKlein-Hitpass, L., Ryffel, G. U., Heitlinger, E., & Cato, A. C. B. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.2.647 · Cited by 429
Yang, N. N., Venugopalan, M., Hardikar, S., & Glasebrook, A. (1996) · Science · doi:10.1126/science.273.5279.1222 · Cited by 429
Fawell, S. E., White, R., Hoare, S., Sydenham, M., Page, M., & Parker, M. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6883 · Cited by 396
Gottardis, M. M., & Jordan, V. C. (1987) · PubMed · Cited by 378
McDonald, C. C., & Stewart, H. J. (1991) · BMJ · doi:10.1136/bmj.303.6800.435 · Cited by 365
Osborne, C. K., Coronado-Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McCleland, R. A., Manning, D. L., & Nicholson, R. I. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.10.746 · Cited by 361
Self-citationLien, E. A., Solheim, E., & Ueland, P. M. (1991) · PubMed · Cited by 356
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
Howell, A., DeFriend, D. J., Blamey, R. W., Robertson, J. F., & Walton, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91156-1 · Cited by 349
Lee, A. V. (1999) · Molecular Endocrinology · doi:10.1210/me.13.5.787 · Cited by 340
Rutqvist, L. E., & Anders Mattsson for the Stockholm Breast Cancer Study Group (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.17.1398 · Cited by 334
Effects of anti-estrogens on bone in castrated and intact female rats
Jordan, V. C., Phelps, E., & Lindgren, J. U. (1987) · Breast Cancer Research and Treatment · doi:10.1007/bf01806132 · Cited by 324
Symptoms Associated With Tamoxifen Treatment in Postmenopausal Women
Love, R. R. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400090120021 · Cited by 273
Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., & Williams, G. M. (1993) · PubMed · Cited by 265
'Nolvadex', A. A. E. Y. B., & Adjuvant Trial Organisation. (1988) · British Journal of Cancer · doi:10.1038/bjc.1988.138 · Cited by 250
Montano, M. M. (1995) · Molecular Endocrinology · doi:10.1210/me.9.7.814 · Cited by 246
A comparison of transcriptional activation by ERα and ERβ
Cowley, S. M., & Parker, M. G. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(99)00055-2 · Cited by 243
Antagonism of estrogen action with a new benzothiophene derived antiestrogen
Black, L. J., Jones, C. D., & Falcone, J. F. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90935-9 · Cited by 239
Proteasomal regulation of nuclear receptor corepressor-mediated repression
Zhang, J., Guenther, M. G., Carthew, R. W., & Lazar, M. A. (1998) · Genes & Development · doi:10.1101/gad.12.12.1775 · Cited by 223
The Scottish Cancer Trials Breast Group, Stewart, H., Forrest, A., Everington, D., McDonald, C., Dewar, J., Hawkins, R., Prescott, R., & George, W. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.356 · Cited by 177
Palkowitz, A. D., Glasebrook, A. L., Thrasher, K. J., Hauser, K. L., Short, L. L., Phillips, D. L., Muehl, B. S., Sato, M., Shetler, P. K., Cullinan, G. J., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970167b · Cited by 177
Clemens, J. A., Bennett, D. R., Black, L. J., & Jones, C. D. (1983) · Life Sciences · doi:10.1016/0024-3205(83)90323-5 · Cited by 176
Original article: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
Howell, A., Dodwell, D. J., Anderson, H., & Redford, J. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058286 · Cited by 172
Tamoxifen: A Reappraisal of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use
Buckley, M. M.-T., & Goa, K. L. (1989) · Drugs · doi:10.2165/00003495-198937040-00004 · Cited by 167
Chlebowski, R. T., Collyar, D. E., Somerfield, M. R., & Pfister, D. G. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1939 · Cited by 164
Ke, H. Z., Paralkar, V. M., GRASSER, W. A., Crawford, D. T., Qi, H., Simmons, H. A., Pirie, C. M., Chidsey-Frink, K. L., Owen, T. A., Smock, S. L., et al. (1998) · Endocrinology · doi:10.1210/endo.139.4.5902 · Cited by 161
Lykkesfeldt, A. E., Madsen, M. W., & Briand, P. (1994) · PubMed · Cited by 160
Jordan, V. C., Fritz, N. F., & Tormey, D. C. (1987) · PubMed · Cited by 152
Antiestrogens – Tamoxifen, SERMs and Beyond
Dhingra, K. (1999) · Investigational New Drugs · doi:10.1023/a:1006348907994 · Cited by 148
Rutqvist, L. E., Cedermark, B., Glas, U., Mattsson, A., Skoog, L. K., Somell, A., Theve, T., Wilking, N. E., Askergren, J., Hjalmar, M.-L., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.18.1299 · Cited by 147
Willson, T. M., Henke, B. R., Momtahen, T. M., Charifson, P. S., Batchelor, K. W., Lubahn, D. B., Moore, L. B., Oliver, B. B., Sauls, H. R., Triantafillou, J. A., et al. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00037a002 · Cited by 146
Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth
O'Regan, R. M., Cisneros, A., MacGregor, J. L., Muenzner, H. D., Assikis, V. J., Piette, M., Jordan, V. C., England, G. M., Bilimoria, M. M., Chatterton, R. T., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.20.1552 · Cited by 140
Grese, T. A., Pennington, L. D., Sluka, J. P., Adrian, M. D., Cole, H. W., Fuson, T. R., Magee, D. E., Phillips, D. L., Rowley, E. R., Shetler, P. K., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970688z · Cited by 138
LY353381.HCl: A Novel Raloxifene Analog with Improved SERM Potency and Efficacy In Vivo
Sato, M., Turner, C. H., Wang, T., Adrian, M. D., Rowley, E. R., & Bryant, H. U. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37755-9 · Cited by 136
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth
Osborne, C. K., Jarman, M., McCague, R., Coronado, E. B., Hilsenbeck, S. G., & Wakeling, A. E. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685924 · Cited by 133
Self-citationThe future of new pure antiestrogens in clinical breast cancer
Wakeling, A. E. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00662395 · Cited by 131
Willson, T. M., Norris, J. D., Wagner, B. L., Asplin, I., Baer, P. G., Brown, H. R., Jones, S. A., Henke, B. R., Sauls, H. R., Wolfe, S. G., et al. (1997) · Endocrinology · doi:10.1210/en.138.9.3901 · Cited by 131
Gottardis, M. M., Ricchio, M. E., SATYASWAROOP, P. G., et al. (1990) · PubMed · Cited by 128
Marttunen, M. B., Hietanen, P. S., Tiitinen, A. E., & Ylikorkala, O. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.4.4688 · Cited by 127
Tomás, E. I., Kauppila, A., BLANCO, G., et al. (1995) · Gynecologic Oncology · doi:10.1006/gyno.1995.0019 · Cited by 117
Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats
Ke, H. Z., Simmons, H. A., Pirie, C. M., Crawford, D. T., & Thompson, D. D. (1995) · Endocrinology · doi:10.1210/endo.136.6.7750465 · Cited by 114
Vogel, C. L., Shemano, I., Schoenfelder, J. R., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.2.345 · Cited by 114
Webster, N. J., Green, S., Tasset, D. M., Ponglikitmongkol, M., & Chambon, P. (1989) · The EMBO Journal · doi:10.1002/j.1460-2075.1989.tb03526.x · Cited by 106
Wade, G. N., Blaustein, J. D., Gray, J., & Meredith, J. M. (1993) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1993.265.6.r1392 · Cited by 105
The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats
Gallagher, A. C., Chambers, T. J., & Tobias, J. H. (1993) · Endocrinology · doi:10.1210/endo.133.6.8243306 · Cited by 100
Robinson, S. P., & Jordan, V. C. (1989) · PubMed · Cited by 95
Gynecologic effects of tamoxifen and the association with endometrial carcinoma
Assikis, V. J., & Jordan, V. C. (1995) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(95)02387-r · Cited by 94
NUTTALL, M. E., Bradbeer, J. N., Stroup, G. B., Nadeau, D. P., Hoffman, S. J., Zhao, H. Q., Rehm, S., & Gowen, M. (1998) · Endocrinology · doi:10.1210/endo.139.12.6343 · Cited by 94
Self-citationUse of pure antioestrogens to elucidate the mode of action of oestrogens
Wakeling, A. E. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00528-t · Cited by 88
Poulin, R., Merand, Y., Poirier, D., Levesque, C., Dufour, J.-M., & Labrie, F. (1989) · Breast Cancer Research and Treatment · doi:10.1007/bf01805977 · Cited by 86
Chander, S. K., McCague, R., Luqmani, Y. A., et al. (1991) · PubMed · Cited by 84
Hyder, S. M., Chiappetta, C., Murthy, L. J., & Stancel, G. M. (1997) · PubMed · Cited by 76
Simard, J., Labrie, C., Bélanger, A., Gauthier, S., Singh, S. M., Mérand, Y., & Labrie, F. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970926)73:1<104::aid-ijc16>3.0.co;2-g · Cited by 75
Tamoxifen resistance in breast cancer
Wiebe, V. J., Osborne, C. K., Fuqua, S. A. W., & DeGregorio, M. W. (1993) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(93)90008-r · Cited by 74
Self-citationWilliams, J. K., Wagner, J. D., Li, Z., Golden, D. L., & Adams, M. R. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.2.403 · Cited by 74
Fraser, R., Heard, D. J., Adam, S., Lavigne, A.-C., Douarin, B. L., Tora, L., Losson, R., Rochette‐Egly, C., & Chambon, P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16199 · Cited by 68
Johnston, S. R. D., Boeddinghaus, I., Riddler, S., Haynes, B. P., Hardcastle, I. R., Rowlands, M. G., Grimshaw, R., Jarman, M., & Dowsett, M. (1999) · PubMed · Cited by 58
Balfour, J. A. B., & Goa, K. L. (1998) · Drugs & Aging · doi:10.2165/00002512-199812040-00006 · Cited by 57
Wiseman, L. R., & Goa, K. L. (1997) · Drugs · doi:10.2165/00003495-199754010-00014 · Cited by 55
Couillard, S., Gutman, M., Labrie, C., Bélanger, A., Candas, B., & Labrie, F. (1998) · PubMed · Cited by 46
Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors
Martel, C., Provencher, L., Li, X., Pierre, A. S., Leblanc, G., Gauthier, S., Mérand, Y., & Labrie, F. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)00192-1 · Cited by 45
Tamoxifen and Secondary Tumours: An Update
Wilking, N. E., Isaksson, E., & Schoultz, E. V. (1997) · Drug Safety · doi:10.2165/00002018-199716020-00003 · Cited by 36
Muss, H. B., Smith, L. R., & Cooper, M. R. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1556 · Cited by 26
Luo, S., Martel, C., Gauthier, S., Mérand, Y., Bélanger, A., Labrie, C., & Labrie, F. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971127)73:5<735::aid-ijc21>3.0.co;2-3 · Cited by 21
Blin‐Wakkach, C., L’Horset, F., Leclerc, T., Lambert, M., Colnot, S., THOMASSET, M., & Perret, C. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00154-r · Cited by 19
Galman, M. S., Sundstrom, S. A., & Lyttle, C. R. (1990) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(90)90218-h · Cited by 15
The Estrogenic and Antiestrogenic Activities of Droloxifene in Human Breast Cancers
Kawamura, I., MIZOTA, T., Lacey, E., Tanaka, Y., Manda, T., Shimomura, K., & KOHSAKA, M. (1993) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.63.27 · Cited by 15
Phase II and III clinical trials of toremifene for metastatic breast cancer.
Vogel, C. L. (1998) · PubMed · Cited by 15
Cited by
LXRS AND FXR: The Yin and Yang of Cholesterol and Fat Metabolism
Kalaany, N. Y., & Mangelsdorf, D. J. (2006) · Annual Review of Physiology · doi:10.1146/annurev.physiol.68.033104.152158 · Cited by 615
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., & Senn, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3817 · Cited by 582
A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer
Musa, M., Cooperwood, J., & Khan, M. O. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708786242877 · Cited by 538
Biology of Progesterone Receptor Loss in Breast Cancer and Its Implications for Endocrine Therapy
Cui, X., Schiff, R., Arpino, G., Osborne, C. K., & Lee, A. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.004 · Cited by 514
Self-citationOsborne, C. K., Shou, J., Massarweh, S., & Schiff, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.865s.11.2 · Cited by 462
Self-citation
Metadata
- Authors
- Osborne, C. K., Zhao, H. (., & Fuqua, S. A. W.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-09-17
- Volume
- 18
- Issue
- 17
- Pages
- 3172-3186
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1955010715
- Cited by
- 367
- References
- 113
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.